HAE · Haemonetics Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q3 '26 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $321.39M | $338.97M | $327.31M | $336.17M | $348.54M | $345.51M | $311.33M | $336.25M | $318.18M | $297.49M |
| Cost of Revenue | $129.15M | $136.58M | $132.57M | $161.25M | $155.00M | $158.07M | $144.07M | $158.38M | $147.67M | $139.61M |
| Gross Profit | $192.24M | $202.39M | $194.74M | $174.92M | $193.55M | $187.44M | $167.26M | $177.87M | $170.51M | $157.88M |
| R&D | $16.26M | $14.19M | $14.87M | $14.45M | $15.83M | $16.53M | $12.65M | $13.27M | $12.66M | $10.90M |
| SG&A | $110.72M | $109.15M | $101.61M | $108.25M | $106.46M | $106.95M | $93.48M | $111.71M | $104.90M | $92.41M |
| Total Operating Expenses | $138.37M | $134.99M | $136.25M | $135.17M | $134.52M | $135.74M | $113.61M | $131.89M | $135.21M | $111.15M |
| D&A | $28.76M | $27.39M | $29.22M | $29.14M | $15.20M | $15.00M | $23.03M | $14.20M | $12.90M | - |
| Operating Income | $53.87M | $67.40M | $58.49M | $39.76M | $59.03M | $51.70M | $53.66M | $45.98M | $35.30M | $46.73M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $11.14M | $15.23M | $12.60M | $8.34M | $12.42M | $10.87M | $10.55M | $12.79M | $7.92M | $7.86M |
| Net Income | $34.03M | $44.74M | $38.68M | $38.37M | $37.49M | $33.83M | $41.04M | $31.24M | $24.91M | $33.20M |
| EPS - Basic | $0.71 | $0.96 | $0.81 | $0.75 | $0.75 | $0.66 | $0.81 | $0.62 | $0.49 | $0.65 |
| EPS - Diluted | $0.70 | $0.95 | $0.81 | $0.74 | $0.74 | $0.66 | $0.80 | $0.61 | $0.48 | $0.64 |
Balance Sheet
| Line item | Q1 '26 | Q3 '26 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $245.44M | $363.37M | $296.43M | $306.76M | $320.85M | $299.28M | $178.80M | $193.98M | $351.00M | $284.47M |
| Accounts Receivable | $216.85M | $195.71M | $207.07M | $202.66M | $211.95M | $213.53M | $206.56M | $211.61M | $174.25M | $179.14M |
| Inventory | $306.37M | $321.19M | $336.21M | $365.14M | $359.61M | $382.11M | $317.20M | $304.02M | $285.83M | $259.38M |
| Accounts Payable | $51.06M | $48.69M | $61.69M | $67.00M | $62.99M | $69.24M | $73.36M | $56.84M | $80.16M | $63.93M |
| Current Assets | $834.88M | $943.67M | $899.68M | $934.98M | $1.01B | $955.90M | $768.90M | $764.98M | $865.74M | $769.72M |
| Total Assets | $2.40B | $2.49B | $2.44B | $2.45B | $2.53B | $2.53B | $2.20B | $2.20B | $2.01B | $1.93B |
| Current Liabilities | $282.60M | $539.87M | $548.32M | $578.11M | $253.23M | $273.95M | $300.38M | $261.75M | $264.21M | $251.82M |
| Long-term Debt | $1.22B | $919.99M | $920.39M | $921.23M | $1.22B | $1.22B | $797.56M | $856.85M | $748.66M | $754.10M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $796.32M | $911.45M | $849.17M | $820.84M | $906.86M | $878.85M | $959.96M | $943.32M | $893.66M | $818.00M |
| Retained Earnings | $279.34M | $381.09M | $336.32M | $352.17M | $392.23M | $368.54M | $360.46M | $340.10M | $308.90M | $253.17M |
Cash Flow
| Line item | Q1 '26 | Q3 '26 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $17.39M | - | - | ($27.42M) | - | - | $19.09M | - | - | - |
| Investing Cash Flow | ($33.00M) | - | - | ($139.20M) | - | - | ($15.26M) | - | - | - |
| Financing Cash Flow | ($2.44M) | - | - | $333.69M | - | - | ($598.0K) | - | - | - |
| CapEx | $3.75M | - | - | $5.66M | - | - | $9.66M | - | - | - |
| Free Cash Flow | $13.64M | - | - | ($33.08M) | - | - | $9.42M | - | - | - |
Ratios
| Metric | Q1 '26 | Q3 '26 | Q2 '26 | Q1 '25 | Q3 '25 | Q2 '25 | Q1 '24 | Q3 '24 | Q2 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 59.8% | 59.7% | 59.5% | 52.0% | 55.5% | 54.2% | 53.7% | 52.9% | 53.6% | 53.1% |
| Operating margin | 16.8% | 19.9% | 17.9% | 11.8% | 16.9% | 15.0% | 17.2% | 13.7% | 11.1% | 15.7% |
| EBITDA margin | 25.7% | 28.0% | 26.8% | 20.5% | 21.3% | 19.3% | 24.6% | 17.9% | 15.1% | - |
| Net margin | 10.6% | 13.2% | 11.8% | 11.4% | 10.8% | 9.8% | 13.2% | 9.3% | 7.8% | 11.2% |
| Free cash flow margin | 4.2% | - | - | -9.8% | - | - | 3.0% | - | - | - |
| FCF / Net income | 0.40 | - | - | -0.86 | - | - | 0.23 | - | - | - |
| R&D / Revenue | 5.1% | 4.2% | 4.5% | 4.3% | 4.5% | 4.8% | 4.1% | 3.9% | 4.0% | 3.7% |
| SG&A / Revenue | 34.4% | 32.2% | 31.0% | 32.2% | 30.5% | 31.0% | 30.0% | 33.2% | 33.0% | 31.1% |
| Effective tax rate | 24.7% | 25.4% | 24.6% | 17.9% | 24.9% | 24.3% | 20.4% | 29.0% | 24.1% | 19.1% |
| Return on assets | 1.4% | 1.8% | 1.6% | 1.6% | 1.5% | 1.3% | 1.9% | 1.4% | 1.2% | 1.7% |
| Return on equity | 4.3% | 4.9% | 4.6% | 4.7% | 4.1% | 3.8% | 4.3% | 3.3% | 2.8% | 4.1% |
| Return on invested capital | 2.0% | 2.7% | 2.5% | 1.9% | 2.1% | 1.9% | 2.4% | 1.8% | 1.6% | 2.4% |
| Liquidity | ||||||||||
| Current ratio | 2.95 | 1.75 | 1.64 | 1.62 | 3.97 | 3.49 | 2.56 | 2.92 | 3.28 | 3.06 |
| Quick ratio | 1.87 | 1.15 | 1.03 | 0.99 | 2.55 | 2.09 | 1.50 | 1.76 | 2.19 | 2.03 |
| Cash ratio | 0.87 | 0.67 | 0.54 | 0.53 | 1.27 | 1.09 | 0.60 | 0.74 | 1.33 | 1.13 |
| Leverage | ||||||||||
| Debt / Equity | 1.53 | 1.01 | 1.08 | 1.12 | 1.35 | 1.39 | 0.83 | 0.91 | 0.84 | 0.92 |
| Debt / Assets | 0.51 | 0.37 | 0.38 | 0.38 | 0.48 | 0.48 | 0.36 | 0.39 | 0.37 | 0.39 |
| Debt / EBITDA | 14.76 | 9.71 | 10.49 | 13.37 | 16.43 | 18.28 | 10.40 | 14.24 | 15.53 | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 3.01 | 2.73 | 2.88 | 2.99 | 2.79 | 2.87 | 2.29 | 2.33 | 2.25 | 2.37 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.13 | 0.14 | 0.13 | 0.14 | 0.14 | 0.14 | 0.14 | 0.15 | 0.16 | 0.15 |
| Inventory turnover | 0.42 | 0.43 | 0.39 | 0.44 | 0.43 | 0.41 | 0.45 | 0.52 | 0.52 | 0.54 |
| Days sales outstanding | 246d | 211d | 231d | 220d | 222d | 226d | 242d | 230d | 200d | 220d |
| Days inventory outstanding | 866d | 858d | 926d | 827d | 847d | 882d | 804d | 701d | 706d | 678d |
| Days payable outstanding | 144d | 130d | 170d | 152d | 148d | 160d | 186d | 131d | 198d | 167d |
| Cash conversion cycle | 968d | 939d | 987d | 895d | 920d | 948d | 860d | 799d | 708d | 731d |
| Valuation | ||||||||||
| P / E | 77.2x | 84.5x | 59.5x | 85.4x | 104.8x | 120.9x | 106.7x | 140.2x | 186.6x | 129.3x |
| P / B | 3.3x | 4.1x | 2.7x | 4.0x | 4.3x | 4.7x | 4.6x | 4.7x | 5.2x | 5.2x |
| P / S | 8.1x | 11.1x | 7.0x | 9.7x | 11.3x | 11.8x | 14.1x | 13.1x | 14.5x | 14.3x |
| EV / EBITDA | 43.4x | 45.7x | 33.3x | 56.2x | 65.0x | 75.1x | 65.2x | 84.1x | 103.8x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -4.4% | -2.7% | -5.3% | 8.0% | 3.7% | 8.6% | 19.1% | 10.1% | 7.0% | 24.0% |
| Revenue CAGR (3y) | 7.1% | 3.5% | 3.2% | 13.7% | 10.3% | 12.9% | 16.8% | 11.8% | 14.9% | 5.6% |
| Revenue CAGR (5y) | 10.4% | 7.1% | 9.3% | 7.1% | 6.1% | 6.5% | 8.1% | 7.5% | 7.1% | - |
| Gross profit growth (YoY) | 9.9% | 4.6% | 3.9% | 4.6% | 8.8% | 9.9% | 17.6% | 12.1% | 8.0% | 28.8% |
| Operating income growth (YoY) | 35.5% | 14.2% | 13.1% | -25.9% | 28.4% | 46.4% | 74.4% | 6.2% | -24.5% | 90.7% |
| Net income growth (YoY) | -11.3% | 19.3% | 14.3% | -6.5% | 20.0% | 35.8% | 106.5% | -5.2% | -25.0% | 123.5% |
| EPS growth (YoY) | -5.4% | 28.4% | 22.7% | -7.5% | 21.3% | 37.5% | 110.5% | -4.7% | -25.0% | 120.7% |
| EPS CAGR (3y) | 22.6% | 14.1% | 8.2% | - | 18.0% | 31.5% | 56.2% | -0.5% | -20.1% | -3.9% |
| EPS CAGR (5y) | 27.2% | 8.9% | -2.9% | - | 5.0% | -1.7% | - | 11.8% | 6.5% | 11.0% |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | 27.1% | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -3.0% | 0.5% | -3.4% | -14.5% | -3.9% | -1.7% | 24.6% | 21.6% | 9.2% | 9.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2026-03-28.
Product / service
$979.32M totalPlasma Productsand Services$524.46M · 53.6%
Hospital Productsand Services$234.01M · 23.9%
Blood Center Productsand Services$220.86M · 22.6%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing HAEMONETICS CORP against the 5 most active filers in the same SIC group.